ライフサイエンスコーパス: DTC

1 DTC cell lines established from the bone marrow of patie

2 DTC extravasation into the bone marrow may be encouraged

3 DTC is rare but frequently results in graft loss and dea

4 DTC status identifies high-risk patients after FEC chemo

5 DTCs were detected in 9.9% of the patients, but not asso

6 tion study in Koreans using a total of 1,085 DTC cases and 8,884 controls, and validated these result

7 Of the 15 DTCs, 6 were renal cell cancer; 5, lung cancer; 2, lymph

8 responses for 62 clinical encounters from 16 DTC telemedicine websites from February 4 to March 11, 2

9 We studied the mechanisms of ziram's (a DTC fungicide) neurotoxicity in vivo.

10 We propose that a DTC analysis may be a sensitive method for assessing the

11 amine this system, we first tested thiram, a DTC pesticide known to display neurotoxic effects, obser

12 Of 1,066 patients with a DTC result at BM2 and available follow-up information (m

13 ting in the field and patients with advanced DTC/MTC now have new standard-of-care therapy options.

14 articipants may not be representative of all DTC PGT consumers.

15 ificant difference between the SUVmax of all DTCs and PDTCs, regardless of BRAF mutational status (P

16 Tel01, distamycin A, and DTC all form complexes with quadruplex DNA, but only Tel

17 gh-risk patients after FEC chemotherapy, and DTC monitoring status after secondary treatment with doc

18 rvival was observed between DTC-negative and DTC-positive patients and was evident in subgroup analys

19 xes to promote leader cell specification and DTC niche function.

20 ry reconstruction analysis of bulk tumor and DTC genomes enables ordering of CNA events in molecular

21 ained from the clinical analyses of CTCs and DTCs, which demonstrate that the animal models mimic, in

22 orphologically classified as tumor cells are DTCs disseminating from the observed tumor.

23 s of varying such experimental parameters as DTC concentration, pH, and methanol content in the runni

24 The hydrodynamic sizes of Au DTCs were estimated by diffusion nuclear magnetic resona

25 The structure and property of the Au DTCs are studied to probe two effects: the entropy gain

26 At baseline, DTCs were detected in 26 of 60 patients in the zoledroni

27 log-rank test) survival was observed between DTC-negative and DTC-positive patients and was evident i

28 for elucidation of the relationship between DTC genomic alterations and progressive prostate cancer.

29 very 3 weeks) were administered, followed by DTC analysis 1 and 13 months after the last docetaxel in

30 DO oxidation with subsequent ring opening by DTC salts, which can be generated in situ from secondary

31 and glycogen metabolism could be altered by DTCs.

32 ent of the glycogenolytic activity of bGP by DTCs such as thiram may be a new mechanism by which cert

33 ne-refractory differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC) in the past 10 y

34 th metastatic differentiated thyroid cancer (DTC) and poorly differentiated thyroid cancer (PDTC).

35 ood tests for differentiated thyroid cancer (DTC) have been introduced into routine clinical practice

36 Differentiated thyroid cancer (DTC) incidence has been reported to have increased three

37 incidence of differentiated thyroid cancer (DTC) is increasing.

38 Although differentiated thyroid cancer (DTC) is typically an indolent disease with a high rate o

39 th metastatic differentiated thyroid cancer (DTC) may be prepared using either thyroid-stimulating ho

40 treatment in differentiated thyroid cancer (DTC) patients.

41 tastases from differentiated thyroid cancer (DTC) using (131)I WB imaging and (124)I PET.

42 ility loci of differentiated thyroid cancer (DTC) were identified by previous genome-wide association

43 ients who had differentiated thyroid cancer (DTC) with that of a matched general population.

44 ems exist for differentiated thyroid cancer (DTC), but all harbor limitations.

45 management of differentiated thyroid cancer (DTC), taking into consideration the methodological conce

46 Differentiated thyroid cancer (DTC), with a rapidly increasing incidence is the most co

47 I)-refractory differentiated thyroid cancer (DTC).

48 ed with the graft (donor-transmitted cancer [DTC]) or develop subsequently from the graft (donor-deri

49 accepting units and di(tert-butyl)carbazole (DTC) as the electron-donating units.

50 ients with differentiated thyroid carcinoma (DTC) into prognostic risk groups.

51 pediatric differentiated thyroid carcinoma (DTC) is excellent.

52 astases in differentiated thyroid carcinoma (DTC) patients with elevated serum thyroglobulin and both

53 Differentiated thyroid carcinoma (DTC), as one of the major component cancers of CS, is th

54 ients with differentiated thyroid carcinoma (DTC).

55 The distal tip cell (DTC) caps a blind-ended tube; only the distal germ cells

56 Analysis of distal tip cell (DTC) migration during gonadogenesis in Caenorhabditis el

57 factor required for proper distal tip cell (DTC) migration.

58 pathway signaling from the distal tip cell (DTC) niche to the germline maintains the progenitor pool

59 ate is specified by somatic distal tip cell (DTC) niche-germline GLP-1 Notch signaling through repres

60 The Caenorhabditis elegans distal tip cell (DTC) provides a niche for germline stem cells in both he

61 lled mesenchymal niche, the distal tip cell (DTC), employs GLP-1/Notch signaling and an RNA regulator

62 vulval precursor cells, the distal tip cell (DTC), intestine, and the lateral hypodermal seam cells b

63 ling cascade in the gonadal distal tip cell (DTC), the germline stem cell niche, where it negatively

64 distal daughter generates a distal tip cell (DTC), which is required for stem cell maintenance.

65 sion of HA-betatail in the distal tip cells (DTC), the cells that direct gonad morphogenesis.

66 e from the pool of disseminated tumor cells (DTC) that survive adjuvant or neoadjuvant therapy, and p

67 Disseminated tumor cells (DTC), which share mesenchymal and epithelial properties,

68 anced disease, are disseminated tumor cells (DTC).

69 al lineage both to specify distal tip cells (DTCs) and in DTC differentiation and function.

70 two specialized C. elegans distal tip cells (DTCs) provide an in vivo model system for the study of d

71 in the hypodermis, muscle, distal tip cells (DTCs), and in neurons.

72 rmined by migration of the distal tip cells (DTCs).

73 d arm migration led by the distal tip cells (DTCs).

74 r cells (CTCs) and disseminated tumor cells (DTCs) are increasingly recognized for their potential ut

75 r cells (CTCs) and disseminated tumor cells (DTCs) in bone marrow (BM) in patients with colorectal li

76 The presence of disseminated tumor cells (DTCs) in bone marrow (BM) predicts survival in early bre

77 These dormant disseminated tumor cells (DTCs) may reside in close proximity to osteoblasts, whil

78 These disseminated tumor cells (DTCs) may resist therapy and lay dormant or progress to

79 d on clearance of disseminated tumour cells (DTCs) from the bone marrow in women undergoing neoadjuva

80 an originate from disseminated tumour cells (DTCs), which may be dormant for years before reactivatio

81 iram may be a new mechanism by which certain DTCs exert their neurotoxic effects.

82 lkaloid family, d-(+)-tubocurarine chloride (DTC), has been evaluated as a chiral selector for the se

83 nitial studies, the detection of circulating DTC cells by thyrotropin receptor (TSHR) mRNA measuremen

84 to synthesize dithiol-protected Au clusters (DTCs).

85 ort (ETC) and the definitive therapy cohort (DTC).

86 Although direct-to-consumer (DTC) advertisements for pharmaceuticals have been appear

87 asing public interest in direct-to-consumer (DTC) genetic ancestry testing has been accompanied by gr

88 but is available through direct-to-consumer (DTC) genetic testing companies.

89 Direct-to-consumer (DTC) genetic testing has attracted a great amount of att

90 able developments in the direct-to-consumer (DTC) genomic testing arena, in particular with regard to

91 Direct-to-consumer (DTC) personal genomic testing (PGT) allows individuals t

92 to big-data methods and direct-to-consumer (DTC) strategies.

93 ity of rapidly expanding direct-to-consumer (DTC) telemedicine websites and smartphone apps diagnosin

94 me tests are now offered direct-to-consumer (DTC) via genetic variants identified by genome-wide asso

95 N-1 is required cell-autonomously to control DTC migration.

96 y, and in parallel to ced-10/Rac, to control DTC pathfinding.

97 n where it acts cell-autonomously to control DTC turning.

98 A days to criterion (DTC) analysis was used to determine delays in acquisitio

99 The clinical application of CTC/DTC requires better understanding of the biological mech

100 ces the role of MIG-15 in integrin-dependent DTC turning.

101 d not receive zoledronic acid had detectable DTCs (p=0.054).

102 t was the number of patients with detectable DTCs at 3 months.

103 juvant therapy, and patients with detectable DTCs following therapy are at substantially increased ri

104 y tests the ability of TSHR mRNA to diagnose DTC preoperatively and to detect cancer recurrence.

105 mitosis is not restricted to areas of direct DTC-germ line contact and that the germ line shares a co

106 ing kinase (NIK) works with MIG-38 to direct DTC turning as shown by mig-38 RNAi with the mig-15(rh80

107 for metastatic capacity in advanced-disease DTCs and for variation in that capacity in DTCs from loc

108 posure to the commonly used dithiocarbamate (DTC) pesticides is associated with an increased risk of

109 Dithiocarbamates (DTCs) are important industrial chemicals used extensivel

110 Dithiocarbamates (DTCs) were recently discovered as carbonic anhydrase (CA

111 ich were also analysed for dithiocarbamates (DTCs) using a spectrophotometric method.

112 icle, we evaluate glycosyl dithiocarbamates (DTCs) with unprotected C2 hydroxyls as donors in beta-li

113 used in the production of dithiocarbamates (DTCs), which are potent fungicides and pesticides, thus

114 n vivo, growth arrest or survival of dormant DTCs is interrupted in different organs.

115 deaths in 11 cases) as opposed to late DTC (DTC-related deaths in 3 of 4 cases).

116 126) indicate that CACN-1 is required during DTC migration for proper pathfinding and for cessation o

117 Early DTC (diagnosed </=6 weeks of transplantation) showed a b

118 Forty-eight DTC and 34 PDTC patients who underwent (18)F-FDG PET/CT

119 d, resulting in either an absent or an extra DTC.

120 f POP-1/TCF or SYS-1/beta-catenin, and extra DTCs are made upon overexpression of SYS-1/beta-catenin.

121 new factors with prognostic implications for DTC.

122 he down-regulation of ina-1 is necessary for DTC migration cessation and the up-regulation of pat-2 i

123 Dissociation patterns for DTC/quadruplex complexes are similar to those of distamy

124 This emphasizes the potential for DTC analysis as a surrogate marker for adjuvant treatmen

125 potential risk stratification predictors for DTC.

126 voidance of radioactive iodine treatment for DTC, when appropriate.

127 ivary gland dysfunction during follow-up for DTC patients receiving high-activity radioiodine treatme

128 mRNA >1 ng/mug had 96% predictive value for DTC, whereas 95% of patients with undetectable mRNA and

129 f 72 docetaxel-treated patients analyzed for DTCs after treatment, 15 (20.8%) had persistent DTCs.

130 Four DTC patients at MedStar Washington Hospital Center were

131 TC, were suspected of having metastasis from DTC (e.g., elevated thyroglobulin level without thyroglo

132 Glycosyl DTC couplings are highly beta-selective despite the abse

133 Glycosyl DTCs are readily activated with Cu(I) or Cu(II) triflate

134 pot conversion of glycals into beta-glycosyl DTCs via DMDO oxidation with subsequent ring opening by

135 analyzed 2,428 consecutive patients who had DTC and underwent treatment from 1965 to 2013 at the Dep

136 rom 2006 to 2010 recruiting patients who had DTC, were suspected of having metastasis from DTC (e.g.,

137 Overall 120 (32.4%) patients harbored DTC in their bone marrow.

138 However, DTCs also have recognized medicinal use in the treatment

139 first evidence that the UPR is activated in DTC in the bone marrow from cancer patients, warranting

140 th to specify distal tip cells (DTCs) and in DTC differentiation and function.

141 Several new factors that may be involved in DTC risk stratification have emerged, such as thyroid st

142 rial of VEGF-targeted therapy (sorafenib) in DTC were presented in June 2013, and two phase III trial

143 evelopment of targeted systemic therapies in DTC and MTC in the past 5 years is incredibly exciting i

144 In DTCs isolated from bone marrow specimens from breast can

145 ell carcinoma (HNSCC) dormancy models and in DTCs from prostate cancer patients carrying dormant dise

146 e DTCs and for variation in that capacity in DTCs from localized disease.

147 tic programmes of quiescence and survival in DTCs.

148 gy and reported the prevalence of incidental DTC (iDTC).

149 med to estimate the prevalence of incidental DTC in published autopsy series and determine whether th

150 mycin A, and diethylthiocarbocyanine iodide (DTC) to the parallel stranded G4-quadruplex [d(T2G5T)]4

151 factors, treatment, and outcome of juvenile DTC.

152 initial treatment for patients with juvenile DTC.

153 lated deaths in 11 cases) as opposed to late DTC (DTC-related deaths in 3 of 4 cases).

154 ase diagnosis and treatment provided by many DTC telemedicine websites.

155 d dosimetry for (131)I therapy of metastatic DTC when the same patient was prepared with and imaged a

156 ion methods for (131)I therapy of metastatic DTC.

157 In addition to abnormal migration, DTC fate is affected, resulting in either an absent or a

158 If one or more DTCs were present at BM2, six cycles of docetaxel (100 m

159 These data suggest that BRAF(V600E)-mutated DTCs are significantly more (18)F-FDG-avid than BRAF-WT

160 ive (18)F-FDG PET/CT in radioiodine-negative DTC patients with elevated and rising thyroglobulin.

161 dose) in 15 consecutive radioiodine-negative DTC patients with elevated and rising thyroglobulin.

162 transplantation) showed a better outcome (no DTC-related deaths in 11 cases) as opposed to late DTC (

163 No DTCs are produced in the absence of POP-1/TCF or SYS-1/b

164 nced relapse) compared with patients with no DTCs after treatment (adjusted hazard ratio, 7.58; 95% C

165 The docetaxel-treated patients with no DTCs after treatment had comparable DFI (8.8% experience

166 rienced relapse) compared with those with no DTCs both at BM1 and BM2 (12.7% experienced relapse; P =

167 oidal extension and 1 point for nonpapillary DTC.

168 ronic record system to identify 614 cases of DTC managed at our institution from 1987 to 2006.

169 for proper pathfinding and for cessation of DTC migration at the end of larval morphogenesis.

170 soionic point, and solution conformation, of DTC were determined.

171 Given the expansion of DTC genetic tests, this study highlights the need for fu

172 hose depletion by RNAi results in failure of DTC turning so that DTCs continue their migration away f

173 eir services, the possible adverse impact of DTC genetic testing on healthcare systems, and concern a

174 le of prophylactic CLND in the management of DTC.

175 To dissect the mechanism of DTC turning, we examined the role of a novel gene, F40F1

176 Significantly more foci of metastases of DTC may be identified in patients prepared with THW than

177 A comprehensive picture of DTC PGT consumers who shared their results with a health

178 The presence of DTC in bone marrow is a strong and independent prognosti

179 Presence of DTC significantly correlated with aggressive tumor biolo

180 everal suggestions to improve the quality of DTC telemedicine websites and apps and avoid further gro

181 n transcription factor is a key regulator of DTC specification.

182 a genome-wide RNAi screen for regulators of DTC migration.

183 rospective study the prognostic relevance of DTC in bone marrow for the natural postoperative course

184 iovascular disease, 39 (7.4%) as a result of DTC, and 39 (7.4%) as a result of other/unknown causes.

185 rly differentiated and oxyphilic subtypes of DTC.

186 In terms of DTC genomic testing for disease susceptibility, most of

187 Recent advances in the understanding of DTC tumor biology hold promise for improving the ability

188 In long-term follow-up of DTC patients with thyroglobulin antibodies, 96% with und

189 thermore, we identified specific variants of DTC that have different effects according to cancer type

190 gene NANOG, which contributes to dormancy of DTCs in the bone marrow.

191 Recent research using animal models of DTCs and CTCs have provided novel insights into these pr

192 The molecular nature of DTCs remains elusive, as well as when and from where in

193 quencing to identify and trace the origin of DTCs in breast cancer.

194 the subsequent surrogate marker potential of DTCs for outcome determination.

195 Presence of DTCs in BM was determined by immunocytochemistry using p

196 behind tumor dissemination, the survival of DTCs, and their activation to aggressive growth from dor

197 mechanistic evidence that bGP is a target of DTCs.

198 have been identified as potential targets of DTCs in the brain, the molecular mechanisms underlying t

199 This study explores the use of DTCs for identification of patients insufficiently treat

200 of zoledronic acid may be through effects on DTCs.

201 Fifty-one DTC patients (32 girls and 19 boys; </= 20 y old; mean a

202 For all other DTC patients, regardless of age or TNM stage, no signifi

203 s after treatment, 15 (20.8%) had persistent DTCs.

204 marker in the surveillance of TgAb-positive DTC patients.

205 tional candidate genes of CS and potentially DTC, we analysed a multi-generation CS-like family with

206 h talin and the MIG-15/NCK-1 complex promote DTC motility and that MIG-38 may act as a negative regul

207 nse activity in patients with RAI-refractory DTC who experienced disease progression while taking pri

208 Yet how Axl regulates DTC proliferation in marrow remains undefined.

209 Patients with remaining DTCs had markedly reduced DFI (46.7% experienced relapse

210 The use of rhTSH in patients with low-risk DTC undergoing thyroid remnant ablation appears to have

211 refractory differentiated thyroid cancer (RR-DTC).

212 ed patients with histologically confirmed RR-DTC stratified by age (</= 65 or > 65 years).

213 for treatment of patients of any age with RR-DTC.

214 Using the same DTC assay, we conditionally express an hlh-12 RNAi-hairp

215 to rescue pat-3 null animals but also showed DTC migration defects.

216 is a powerful approach to identify and study DTCs, yielding insight into metastatic processes.

217 However, the mechanisms supporting DTC survival are poorly understood.

218 CTCs were disclosed with CellSearch System, DTC with immunocytology.

219 distamycin; therefore, it is concluded that DTC interacts with [d(T2G5T)]4 through groove-binding.

220 try, including privacy issues, ensuring that DTC companies provide accurate information about the ris

221 We also show that DTCs from patients with advanced and localized disease s

222 Ai results in failure of DTC turning so that DTCs continue their migration away from the midbody regi

223 atients (BLBLI, 72; carbapenem, 31), and the DTC included 174 (BLBLI, 54; carbapenem, 120).

224 The "distal pool" is maintained by the DTC in an essentially uniform and immature or "stem cell

225 25 bp DAF-3 binding element required for the DTC lag-2 reporter response to the environment and to DA

226 4% for the ETC and 9.3% versus 16.7% for the DTC, respectively (P > .2, log-rank test).

227 ative zone cells that are displaced from the DTC niche.

228 liferation in response to signaling from the DTC via the GLP-1/Notch signaling pathway in the germ li

229 DSL ligand family member, is produced in the DTC and activates the GLP-1/Notch receptor on adjacent g

230 In the DTC cohort, 24 tumors harbored a BRAF(V600E) mutation, w

231 ignaling promotes expression of lag-2 in the DTC in a daf-3-dependent manner.

232 xpress an hlh-12 RNAi-hairpin and induce the DTC migration defect.

233 these conserved molecular regulators of the DTC niche in nematodes may provide insight into specific

234 Consumer satisfaction with the DTC PGT experience; whether and, if so, how many results

235 Within the DTC group, TSH level was predictive for cardiovascular m

236 mportant for integrin activation, causes the DTCs to stop migration prematurely.

237 Strong expression of CACN-1 in the DTCs, and data from cell-specific RNAi depletion experim

238 lar pseudo-time and traced the origin of the DTCs to either the main tumor clone, primary tumor subcl

239 rithiocarbonate, structurally related to the DTCs, were prepared by reaction of alcohols/thiols with

240 mordium, and expression continues throughout DTC migration where it acts cell-autonomously to control

241 At this time, DTC advertisements are inappropriate, given the public's

242 ic and molecular alterations contributing to DTC survival.

243 f any studies that have examined response to DTC genetic testing for ancestry or for drug response.

244 Ultimately, DTC genomic testing for common markers and conditions is

245 526), postoperatively in patients undergoing DTC follow-up (n = 418) and in patients monitored for kn

246 of 18 different compounds was achieved using DTC as the chiral selector under optimized background el

247 nors (0.06%): 3 were DDC (0.01%) and 15 were DTC (0.05%).

248 71.9 months from the time of BM2), 7.2% were DTC positive.

249 viduals, although it remains unclear whether DTC genomic information will still be attainable.

250 3, FHIT, SEPT11 and SLC24A6) associated with DTC.

251 sociation of autoimmune thyroid disease with DTC is less clear.

252 sociation of autoimmune thyroid disease with DTC, the prognostic significance of TgAb positivity and

253 cible FLP recombinase and can interfere with DTC migration.

254 One hundred patients with DTC (19.1%) died, 22 (4.2%) as a result of cardiovascula

255 y Cox regression analyses; 524 patients with DTC and 1,572 sex- and age-matched controls from a large

256 [IQR], 4.1 to 15.9 years) for patients with DTC and 10.5 years (IQR, 9.9 to 10.9 years) for controls

257 Patients with DTC had an increased risk of cardiovascular and all-caus

258 Furthermore, patients with DTC may benefit from assessment and treatment of cardiov

259 of cabozantinib, five of eight patients with DTC previously treated with a VEGFR-targeted therapy had

260 astasis should be performed in patients with DTC, as suggested by several recent management guideline

261 In patients with DTC, elevated TSHR mRNA levels became undetectable in al

262 ause mortality is increased in patients with DTC, independent of age, sex, and cardiovascular risk fa

263 f US-guided tissue sampling in patients with DTC.

264 adioiodine ablation therapy in patients with DTC.

265 Over 70% of the samples were positive, with DTC present in 46.5%, lambda-cyhalothrin in 37.1%, and o

266 survival was 83% for kidney recipients with DTC compared with 93% for recipients without DTC (P=0.07

267 Of 15 recipients, 3 (20%) recipients with DTC died as a direct consequence of cancer.

268 Recipients with DTC underwent explant/excision (11), chemotherapy (4), a

269 d in a decreased proportion of patients with DTCs detected in the bone marrow at the time of surgery.

270 DTC compared with 93% for recipients without DTC (P=0.077).

271 en appearing in the mass media for 20 years, DTC advertisements for genetic testing have only recentl